Ken Griffin Oncorus, Inc. Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.28 - $0.45 $531,558 - $854,290	-1,898,423 Reduced 98.65%	25,999 $8,000
Q4 2022 Feb 14, 2023	BUY	$0.24 - $0.76 $2,358 - $7,469	9,828 Added 0.51%	1,924,422 $481,000
Q3 2022 Nov 14, 2022	BUY	$0.85 - $1.65 $19,551 - $37,953	23,002 Added 1.22%	1,914,594 $1.63 Million
Q2 2022 Aug 15, 2022	BUY	$1.04 - $1.86 $3,247 - $5,808	3,123 Added 0.17%	1,891,592 $2.38 Million
Q1 2022 May 16, 2022	SELL	$1.44 - $5.62 $3,081 - $12,026	-2,140 Reduced 0.11%	1,888,469 $3.36 Million
Q4 2021 Feb 14, 2022	BUY	$5.03 - $11.63 $40,737 - $94,191	8,099 Added 0.43%	1,890,609 $9.96 Million
Q3 2021 Nov 15, 2021	SELL	$9.29 - $14.27 $171,493 - $263,424	-18,460 Reduced 0.97%	1,882,510 $17.6 Million
Q2 2021 Aug 16, 2021	BUY	$13.3 - $17.3 $105,535 - $137,275	7,935 Added 0.42%	1,900,970 $26.2 Million
Q1 2021 May 17, 2021	BUY	$11.89 - $35.55 $162,869 - $486,963	13,698 Added 0.73%	1,893,035 $26.4 Million
Q4 2020 Feb 16, 2021	BUY	$15.0 - $35.15 $28.2 Million - $66.1 Million	1,879,337 New	1,879,337 $60.8 Million

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.